Wegovy Authorized as Canada’s First Liver Disease Drug

For years, Canadians living with a serious liver condition known as MASH have been waiting for a breakthrough. Around ~25 per cent of Canadians suffer from liver disease, with an estimated 5.2 per cent of those progressing to a more serious form called MASH.

Up to now, there were no approved medications to treat MASH directly. Patients were often told to focus on diet and exercise while doctors simply monitored their condition, a period of “watchful waiting” that left many feeling anxious and invisible.

That changed on December 10, 2025.

In a historic milestone for Canadian healthcare, Health Canada officially approved the first-ever medication specifically for the treatment of MASH. The drug, Wegovy (semaglutide), has been authorized for adults with moderate to advanced liver scarring.

What is MASH?

MASH (Metabolic dysfunction-Associated Steatohepatitis) is a serious liver disease where excess fat in the liver causes inflammation and cell damage. You may have previously heard this called NASH; the name was recently updated to better reflect that it is a metabolic health issue.

It is a progressive form of liver disease linked to metabolic issues like obesity, type 2 diabetes, and high cholesterol. MASH is particularly dangerous because it is often “silent,” showing no symptoms until it reaches advanced stages. If left untreated, the resulting scarring, which is known as fibrosis, can lead to severe complications like cirrhosis, liver failure, or liver cancer.

A New Tool for Doctors and Patients

Wegovy is a once-weekly injection that belongs to a class of drugs called GLP-1 receptor agonists. In clinical trials, it demonstrated the ability to improve liver health and slow down the progression of scarring.

Health Canada granted the approval under a Notice of Compliance with Conditions (NOC/c). This special pathway is reserved for serious diseases with a high “unmet medical need,” allowing patients access to the medicine while long-term studies continue to confirm its benefits.

Why This Matters

For the millions of Canadians living with MASH, this news is about more than just a new prescription—it is about recognition.

For a long time, patients felt blamed or left behind because there were no pharmaceutical options. This approval validates that MASH is a serious medical condition that requires real therapeutic options, not just lifestyle advice. It reinforces a critical truth: MASH is a metabolic disease, not just a liver condition.

What Happens Next and Cost

As of December 2025, Canadian patients finally have a tangible treatment to discuss with their healthcare teams. This marks the beginning of a new era in liver care focused on:

• Earlier identification: Catching liver damage before it becomes irreversible.
• Risk stratification: Determining which patients need urgent intervention.
• Expanded options: Giving clinicians the tools they need to support their patients effectively.
• Wegovy is generally not covered by provincial public drug plans for weight management alone; provincial drug plans may evolve to cover it for treatment of MASH. Wegovy costs ~$400 per month. Coverage varies significantly by province and at this time requires specific medical criteria, and special authorization. Speak with your healthcare provider and private insurance company to get a comprehensive overview based on your case.

At The Health Insider we hope the conversation around liver health in Canada has officially changed. For the first time, there is a path forward that offers more than just “watchful waiting.” It offers hope. Subscribe today to stay on top of advances in treatment for liver disease.

~ Read more from The Health Insider ~

• 
  No More Fees for Medically Necessary Nurse Practitioner, Pharmacist and Midwife Care
  Starting April 1, 2026, Canada is expanding insured care across the country. Discover how new rules for nurse practitioners, pharmacists and midwives mean fewer out-of-pocket costs for your family.
• 
  The Rot or the Rest? Navigating the “Bed Rotting” Trend
  Is bed rotting self-care or a slump? Discover student perspectives and tips on how to turn this viral rest trend into actual recovery.
• 
  Your Phone Is a Health Tool. Here’s How to Use It
  Your phone might be hurting your health, or helping it. Discover the built-in tools that support better sleep, movement, and focus.
• 
  6 Foods That Help You Poop and Why They Actually Work
  Can’t go? These 6 simple foods may help ease constipation and support more regular digestion, no harsh fixes needed.
• 
  Why Top Surgeons Are Trading Caffeine for Creatine
  It’s not just for the gym. See why your brain is a “metabolic furnace” that uses creatine to prevent fog and fatigue.
• 
  Could ADHD Awareness Lead to False Self-Diagnosis? Researchers Explore the Nocebo Effect
  A study finds ADHD awareness may increase false self-diagnosis in young adults, with researchers pointing to the nocebo effect.

The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.